CLINICAL RESEARCH
Quality of life of patients with chronic obstructive pulmonary disease treated with indacaterol
and/or glycopyrronium: a real-world Polish observational study
Submission date: 2018-11-18
Final revision date: 2018-11-29
Acceptance date: 2018-11-29
Publication date: 2018-12-28
Arch Med Sci Civil Dis 2018;3(1):202-209
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The aim of this study was to evaluate the impact of routinely administered treatment with indacaterol and/or glycopyrronium on quality of life and level of dyspnoea of patients with chronic obstructive pulmonary disease (COPD) in a real-life setting.
Material and methods:
It was an observational, non-interventional study in patients with stable, symptomatic chronic obstructive pulmonary disease initiating treatment with indacaterol and/or glycopyrronium as part of routine care. The primary outcomes included a change in quality of life measured using the Clinical COPD Questionnaire (CCQ) and level of dyspnoea evaluated using the modified Medical Research Council scale (mMRC). Patients were followed up for 6 months after initiation of treatment.
Results:
Analysis included baseline data from 586 patients. At 6 months 82.5% (n = 483) of patients were continuing initiated treatment. Improvement of mMRC and CCQ scores was observed in all treatment arms. The mean total CCQ score ± SD changed after 6 months from 2.2 ±0.9 to 1.2 ±0.9 in the indacaterol group (p < 0.001), from 2.1 ±1.0 to 1.0 ±0.9 (p < 0.001) in the glycopyrronium group and 2.6 ±1.1 at baseline to 1.3 ±1.0 (p < 0.001) in the indacaterol/glycopyrronium group. The mean mMRC ± SD decreased from 2.1 ±0.9 to 1.4 ±0.9 (p < 0.001) in the indacaterol group, from 2.1 ±0.9 to 1.2 ±1.0 (p < 0.001) in the glycopyrronium group, and from 2.3 ±0.8 to 1.4 ±0.9 (p < 0.001) in the indacaterol/glycopyrronium group.
Conclusions:
Use of indacaterol and/or glycopyrronium improved quality of life and breathlessness in patients with stable COPD, efficiently reducing the symptoms burden.
The aim of this study was to evaluate the impact of routinely administered treatment with indacaterol and/or glycopyrronium on quality of life and level of dyspnoea of patients with chronic obstructive pulmonary disease (COPD) in a real-life setting.
Material and methods:
It was an observational, non-interventional study in patients with stable, symptomatic chronic obstructive pulmonary disease initiating treatment with indacaterol and/or glycopyrronium as part of routine care. The primary outcomes included a change in quality of life measured using the Clinical COPD Questionnaire (CCQ) and level of dyspnoea evaluated using the modified Medical Research Council scale (mMRC). Patients were followed up for 6 months after initiation of treatment.
Results:
Analysis included baseline data from 586 patients. At 6 months 82.5% (n = 483) of patients were continuing initiated treatment. Improvement of mMRC and CCQ scores was observed in all treatment arms. The mean total CCQ score ± SD changed after 6 months from 2.2 ±0.9 to 1.2 ±0.9 in the indacaterol group (p < 0.001), from 2.1 ±1.0 to 1.0 ±0.9 (p < 0.001) in the glycopyrronium group and 2.6 ±1.1 at baseline to 1.3 ±1.0 (p < 0.001) in the indacaterol/glycopyrronium group. The mean mMRC ± SD decreased from 2.1 ±0.9 to 1.4 ±0.9 (p < 0.001) in the indacaterol group, from 2.1 ±0.9 to 1.2 ±1.0 (p < 0.001) in the glycopyrronium group, and from 2.3 ±0.8 to 1.4 ±0.9 (p < 0.001) in the indacaterol/glycopyrronium group.
Conclusions:
Use of indacaterol and/or glycopyrronium improved quality of life and breathlessness in patients with stable COPD, efficiently reducing the symptoms burden.
REFERENCES (22)
1.
World Health Organization. Chronic respiratory diseases. Burden of COPD. Available at: www.who.int (Accessed July 10th, 2018).
2.
Jassem E, Górecka D. Severe and terminal chronic obstructive pulmonary disease. Pneumonol Alergol Pol 2009; 77: 411-6.
3.
Śliwiński P, Górecka D, Jassem E, Pierzchała W. Zalecenia Polskiego Towarzystwa Chorób Płuc dotyczące rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc. Pneumonol Alergol Pol 2014, 82: 227-63.
4.
Global Initiative for Chronic Obstructive Pulmonary Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary lung disease. 2018 update. Available at: https://goldcopd.org/ (Accessed July 10th, 2018).
5.
Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209.
6.
Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484-94.
7.
Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013; 107: 1558-67.
8.
Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1: 51-60.
9.
Ministerstwo Zdrowia. Obwieszczenie Ministra Zdrowia w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych. Available at: https://www.gov.pl/zdrowie/obw... (Accessed July 10th, 2018).
10.
Miłkowska-Dymanowska J, Białas AJ, Górski P. Selected aspects of medical care for patients with asthma and chronic obstructive pulmonary disease (COPD) in Poland. Adv Respir Med 2017; 85: 179-85.
11.
van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012; 21: 101-8.
13.
International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP); June 2015.
14.
Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg 2014; 12: 1500-24.
15.
Płusa T. Evaluation of effect of indacaterol (Onbrez) and/or glycopyrronium (Seebri) treatment on Quality of Life of COPD patients in medical practice in Poland – observational study (OSQO). Pol Merkur Lekarski 2017; 43: 158-62.
16.
van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003; 1: 13.
17.
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-6.
18.
Kocks JWH, Tuinenga MG, Uil SM, van den Berg JWK, Ståhl E, van der Molen T Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006; 7: 62.
19.
Jones PW, Kaplan RM. Methodological issues in evaluating measures of health as outcomes for COPD. Eur Respir J Suppl 2003; 41: 13-8.
20.
Sundh J, Janson C, Lissper K, Montgomery S, Ställberg B. Clinical COPD Questionnaire score (CCQ) and mortality. Int J Chron Obstruct Pulmon Dis 2012; 7: 833-42.
21.
Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest 2017; 151: 340-57.
22.
Vogelmeier C, Worth H, Buhl R, et al. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis 2017; 12: 487-94.
Share
RELATED ARTICLE
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
